BidaskClub upgraded shares of Insulet (NASDAQ:PODD) from a sell rating to a hold rating in a report released on Friday, January 26th.
PODD has been the subject of a number of other reports. Morgan Stanley boosted their price objective on Insulet from $55.00 to $63.00 and gave the stock an equal weight rating in a report on Friday, November 3rd. Leerink Swann reaffirmed an outperform rating and issued a $74.00 target price (up from $65.00) on shares of Insulet in a report on Thursday, October 12th. Zacks Investment Research raised Insulet from a sell rating to a hold rating and set a $68.00 target price for the company in a report on Thursday, October 12th. Canaccord Genuity raised Insulet from a hold rating to a buy rating and increased their price objective for the company from $50.00 to $65.00 in a report on Wednesday, November 1st. Finally, Barclays increased their price objective on Insulet from $70.00 to $75.00 and gave the company an overweight rating in a report on Monday, November 20th. Eight research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $62.53.
Insulet (PODD) opened at $73.47 on Friday. Insulet has a 52 week low of $38.43 and a 52 week high of $78.65. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88. The firm has a market capitalization of $4,230.00, a P/E ratio of -146.94 and a beta of 1.59.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Northern Trust Corp raised its holdings in Insulet by 3.2% in the 2nd quarter. Northern Trust Corp now owns 777,986 shares of the medical instruments supplier’s stock worth $39,919,000 after acquiring an additional 24,188 shares during the last quarter. Paulson & CO. Inc. purchased a new position in Insulet in the 2nd quarter worth approximately $1,283,000. Fox Run Management L.L.C. purchased a new position in Insulet in the 3rd quarter worth approximately $435,000. Point72 Asset Management L.P. purchased a new position in Insulet in the 3rd quarter worth approximately $33,373,000. Finally, Bank of New York Mellon Corp raised its holdings in Insulet by 6.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 289,027 shares of the medical instruments supplier’s stock worth $15,919,000 after acquiring an additional 18,111 shares during the last quarter.
TRADEMARK VIOLATION WARNING: “Insulet (PODD) Rating Increased to Hold at BidaskClub” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/13/insulet-podd-upgraded-at-bidaskclub.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.